Inclusion Criteria:  Clinical diagnosis of SLE according to the 1997 American College of Rheumatology (ACR) classification criteria or 2019 EULAR/ACR classification criteria within three months, which is autoantibody-positive (antinuclear antibody titers ≥1:80, anti-double-stranded DNA antibodies, or both) 18-75 years of age body weight 45-80kg Disease duration of SLE ≤ 3months SELENA-SLEDAI score ≥8 scores Negative pregnancy test for child-bearing women at screening and baseline Provide written informed consent  Exclusion Criteria:  Known to be allergic to Prednisone Acetate, Meprednisone, Hydroxychloroquine, and Immunosuppressants including Mycophenolate Mofetil, Cyclophosphamide,et al Active serious neuropsychiatric systemic lupus erythematosus or other severe situations of SLE who need pulse steroid treatment Abnormal liver function (ALT or AST is 2 times higher than normal) Pregnancy or breastfeeding women; Have a history of malignant tumors; Have any serious acute, chronic or recurrent infectious disease (such as pneumonia or active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and tuberculosis) Chronic infections, such as Hepatitis B virus or hepatitis B and C and HIV; Previous visual obstruction, monocular dysfunction and cataract; Cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic pressure > 160mmHg or diastolic pressure > 100mmHg) or diabetics; Physicians will decide whether to use drugs if routine blood test is abnormal WBC<2x109/L or HGB<60g/L or PLT<50x109/L; Active hemorrhage or peptic ulcer; With other concommitant autoimmune disease; Receipt of B-cell-targeted therapy (including belimumab) within 1 year before randomization. Participated in other drugs clinical trials within 4 weeks.